Total Payments
$67,521
2024 Payments
$184.73
Companies
16
Transactions
63
Medicare Patients
1,917
Medicare Billing
$205,563
Payment Breakdown by Category
Research$66,731 (98.8%)
Food & Beverage$790.45 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $66,731 | 18 | 98.8% |
| Food and Beverage | $790.45 | 45 | 1.2% |
Payments by Type
Research
$66,731
14 transactions
General
$790.45
45 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $66,731 | 14 | $0 (2021) |
| Janssen Biotech, Inc. | $288.73 | 18 | $0 (2024) |
| Covidien LP | $107.85 | 1 | $0 (2017) |
| PFIZER INC. | $90.44 | 6 | $0 (2024) |
| ABBVIE INC. | $68.21 | 4 | $0 (2024) |
| Allergan Inc. | $45.33 | 3 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $40.11 | 3 | $0 (2021) |
| Boston Scientific Corporation | $31.16 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $29.88 | 1 | $0 (2022) |
| Organon LLC | $29.00 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $184.73 | 12 | Janssen Biotech, Inc. ($117.70) |
| 2023 | $83.13 | 6 | Janssen Biotech, Inc. ($51.50) |
| 2022 | $145.78 | 9 | Janssen Biotech, Inc. ($72.19) |
| 2021 | $43,254 | 9 | Eli Lilly and Company ($43,188) |
| 2020 | $698.38 | 6 | Eli Lilly and Company ($655.47) |
| 2019 | $1,325 | 8 | Eli Lilly and Company ($1,249) |
| 2018 | $15,493 | 10 | Eli Lilly and Company ($15,419) |
| 2017 | $6,338 | 3 | Eli Lilly and Company ($6,219) |
All Payment Transactions
63 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Immunology | ||||||
| 06/18/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: General - Pain Management_NMD | ||||||
| 06/11/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/29/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Immunology | ||||||
| 03/19/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Immunology | ||||||
| 03/05/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Immunology | ||||||
| 01/09/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Immunology | ||||||
| 2024 | GastroGPO, LLC | — | — | — | $0.00 | Ownership |
| 12/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.14 | General |
| Category: Neuroscience | ||||||
| 11/16/2023 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Immunology | ||||||
| 07/19/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Immunology | ||||||
| 03/07/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Immunology | ||||||
| 2023 | GastroGPO, LLC | — | — | — | $0.00 | Ownership |
| 11/21/2022 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: Immunology | ||||||
| 10/05/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Immunology | ||||||
| 09/28/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: Immunology | ||||||
| 08/24/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Immunology | ||||||
| 06/29/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Immunology | ||||||
| 02/08/2022 | Organon LLC | RENFLEXIS (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: INFLIXIMAB | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $44,190 | 3 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $12,568 | 3 |
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $7,500 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $1,099 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $706.33 | 3 |
| A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | Eli Lilly and Company | $601.03 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $38.60 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $28.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 324 | 496 | $406,973 | $41,820 |
| 2022 | 15 | 441 | 537 | $462,563 | $49,528 |
| 2021 | 14 | 613 | 797 | $443,465 | $64,330 |
| 2020 | 14 | 539 | 688 | $356,587 | $49,886 |
Total Patients
1,917
Total Services
2,518
Medicare Billing
$205,563
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 46 | 46 | $82,846 | $8,979 | 10.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 77 | 77 | $132,825 | $8,609 | 6.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 11 | 119 | $18,088 | $4,242 | 23.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 68 | $6,800 | $3,174 | 46.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 18 | 18 | $24,174 | $3,134 | 13.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 45 | 46 | $69,046 | $3,032 | 4.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 14 | 14 | $18,788 | $2,434 | 13.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $25,498 | $2,284 | 9.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 42 | $6,300 | $2,260 | 35.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $4,862 | $2,123 | 43.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $16,450 | $942.73 | 5.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 16 | $1,296 | $607.52 | 46.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 52 | 52 | $85,231 | $10,113 | 11.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 91 | 92 | $138,750 | $9,227 | 6.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 27 | 27 | $32,472 | $4,776 | 14.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 64 | 64 | $84,040 | $4,414 | 5.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 27 | $7,722 | $4,078 | 52.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 14 | 66 | $10,032 | $2,395 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 31 | $6,869 | $2,289 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $5,462 | $2,245 | 41.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $15,087 | $2,122 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 31 | $4,650 | $1,925 | 41.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 14 | 37 | $3,700 | $1,780 | 48.1% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 15 | 15 | $48,630 | $1,211 | 2.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $15,000 | $1,128 | 7.5% |
About Dr. Peder Pedersen, M.D
Dr. Peder Pedersen, M.D is a Gastroenterology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568558211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peder Pedersen, M.D has received a total of $67,521 in payments from pharmaceutical and medical device companies, with $184.73 received in 2024. These payments were reported across 63 transactions from 16 companies. The most common payment nature is "" ($66,731).
As a Medicare-enrolled provider, Pedersen has provided services to 1,917 Medicare beneficiaries, totaling 2,518 services with total Medicare billing of $205,563. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Salt Lake City, UT
- Active Since 10/04/2006
- Last Updated 06/09/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1568558211
Products in Payments
- STELARA (Biological) $256.55
- Barrx (Device) $107.85
- TREMFYA (Drug) $62.06
- XELJANZ (Drug) $58.83
- RINVOQ (Biological) $34.46
- INFLECTRA (Biological) $31.61
- RENFLEXIS (Drug) $29.00
- RENFLEXIS (Biological) $27.58
- LINZESS (Drug) $25.44
- VIBERZI (Drug) $19.89
- SKYRIZI (Biological) $18.06
- Mavyret (Drug) $15.69
- ZEPOSIA (Drug) $14.14
- GENERAL ENDOCHOICE (Device) $13.33
- Entyvio (Biological) $11.78
- OCALIVA (Drug) $11.72
- Alinia Tablets 500mg 30 count bottle (Drug) $10.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Salt Lake City
Richard Gilroy, Md, MD
Gastroenterology — Payments: $252,278
Gastroenterology $252,278
Kathryn Peterson, Md, MD
Gastroenterology — Payments: $94,047
Gastroenterology $94,047
Amir Kashani
Gastroenterology — Payments: $43,637
Gastroenterology $43,637
Dr. Juan Gallegos-Orozco, M.d, M.D
Gastroenterology — Payments: $30,877
Gastroenterology $30,877
Iqbal Sandhu, Md, MD
Gastroenterology — Payments: $18,270
Gastroenterology $18,270
John Fang, Md, MD
Gastroenterology — Payments: $14,387
Gastroenterology $14,387